Bio-Raid

banner

发布时间:2019-07-09 00:00:00

 

这是描述信息
/
论文
全部分类

论文

  • 分类:科学研究
  • 发布时间:2019-05-29 00:00:00
  • 访问量:0
概要:
概要:
详情

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cellmalignancies.

Wang N1,2, Hu X1,2, Cao W1,2, Li C1,2, Xiao Y1,2, Cao Y1,2, Gu C3,4, Zhang S4, Chen L1,2, Cheng J1,2, Wang G1,2, Zhou X1,2, Zheng M1,2, Mao X1,2,Jiang L1,2, Wang D1,2, Wang Q1,2, Lou Y1,2, Cai H1,2, Yan D5, Zhang Y1,2, Zhang T3,4, Zhou J1,2, Huang L1,2.

 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.

 

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.

 
  2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
 

Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy.

Cao W1Wei J2Wang N3Xu H4Xiao M5Huang L4Cao Y1Li C1Xiao Y1Gu C6Zhang S6Li D1Zhang Y5Zhang T7Zhou J5Huang L5.
 
 2020 Apr 14. pii: blood.2020004907. doi: 10.1182/blood.2020004907.
 
 

Efficacy and Toxicity for CD22/CD19 Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed/Refractory Aggressive B-cell Lymphoma Involving the Gastrointestinal Tract

Chen Zeng 1, Jiali Cheng 1, Tongjuan Li 1, Jin Huang 1, Chunrui Li 1, Lijun Jiang 1, Jue Wang 1, Liting Chen 1, Xia Mao 1, Li Zhu 1, Yaoyao Lou 1, Jianfeng Zhou 1, Xiaoxi Zhou 2
 
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13
 
 

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy

 DOI: 10.1002/ctm2.176

                                                                                                  

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

扫二维码用手机看

Bio-Raid

武汉波睿达生物科技有限公司 

 

公司地址:武汉市东湖新技术开发区高新二路388号

武汉光谷国际生物医药企业加速器3.1期第3幢4层、

5层(1)厂房
联系电话:027-59318269
公司邮箱:
cart@bio-raid.com

 

Bio-Raid

扫码关注
波睿达生物公众号